SOURCE: Bioheart, Inc.

Bioheart, Inc.

October 16, 2013 08:00 ET

Bioheart Announces Contract With African-Middle East Medical (AFRIMID) to Begin Distributing Stem Cell Products in Uganda

SUNRISE, FL--(Marketwired - Oct 16, 2013) - Bioheart, Inc. (OTCQB: BHRT), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced today it has signed a contract with African-Middle East Medical (AFRIMID) to implement Bioheart therapies for the more than 36 million patients in Uganda. Bioheart will begin distributing MyoCell™ (muscle derived stem cells) and AdipoCell™ (adipose derived stem cells) for a variety of indications in Uganda.

"We are looking forward to bringing our therapies to Uganda and expanding the list of indications for our products," said Kristin Comella, Bioheart's Chief Science Officer. "There are many patients who can benefit from regenerative medicine and we are hopeful that these therapies can offer new hope to patients suffering from debilitating diseases."

MyoCell™ is currently under investigation in an FDA Phase II/III US trial for congestive heart failure. AdipoCell™ is currently utilized at Bioheart Centers of Excellence throughout the world for indications including arthritis, limb ischemia, diabetes, heart disease, and more.

"We have many patients with degenerative diseases that could benefit from cellular therapies," said Dr. Robert Basaza, Assistant Commissioner of Health Services of the Uganda Ministry of Health. "We are excited to implement the good scientific work of Bioheart into our clinics in Uganda. It is our intention to make these therapies the standard of care for our country."

About Bioheart, Inc.

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2012, and its Quarterly Report on Form 10-Q for the quarter ended June 31, 2013.

Contact Information

  • Media Contact:
    Alexandra Curbelo
    Wragg & Casas Public Relations
    1221 Brickell Avenue, Suite 730
    Miami, Fl. 33131
    305-372-1234 ex.124